ESPERITE (ESP): issues EUR 400’000 convertible note for additional financing provided by CEO Frederic Amar
ESPERITE N.V. (Euronext: ESP, ‘ESPERITE’, or ‘the Group’) declares the issuance of a convertible loan note of EUR 400’000 to CEO Frederic Amar who has completed the additional financing announced on October 2017.
Amsterdam, the Netherlands – 5 January 2018
This financing contributes positively to the permanent effort initiated by the management to turn around the company and to support the business development.
Mr. Amar has not participated in the decision-making of the Board of Directors regarding the issuance of the note.
The unsecured convertible loan note will bear interest at a rate of 7% per year, payable annually in arrears on 31 December and be convertible into ESPERITE shares until maturity at an initial conversion price of EUR 0.40. This initial conversion price equals ESPERITE’s share price at the time the possible issuance of the note was being discussed and negotiated between the non-executive directors and Mr. Amar. The conversion price may be adjusted in a limited number of customary circumstances. The note will mature on 31 December 2018, unless earlier converted or repurchased. The note will not be listed.
ESPERITE is a diversified biotech global group leader in regenerative and precision medicine. Established in 2000, the holding group is headquartered in the Netherlands, listed at Euronext Amsterdam and Paris and operational in over 30 countries.
ESPERITE transforms the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.
To learn more about the ESPERITE group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – email@example.com or visit the websites at www.esperite.com www.genoma.com and www.cryo-save.com
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.
This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Esperite in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), it being specified that the securities of Esperite have not been and will not be registered within the US Securities Act. Esperite does not intend to register securities or conduct a public offering in the United States of America.